Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Advances in Psoriasis

Advances in Psoriasis EDITORIAL ORE TREATMENTS FOR PSORIASIS HAVE Experience with biologic therapy is analogous to the been introduced during the past 25 introduction of methotrexate for psoriasis. The first ar- years than for all other diseases in der- ticle on methotrexate for this disease was published in matology combined. The impact of 1961. In those days, methotrexate was administered in- M those treatments on all dermatologic travenously, on a daily basis and in dosages as high as disease has been profound. For example, psoralen– 70 mg/wk, and patients died. It was not until 1971 when UV-A was introduced for psoriasis but has changed the Weinstein and Frost published their article about the treatment of cutaneous T-cell lymphoma. Narrowband weekly regimen that is still in use. UV-B was developed for psoriasis but has had a major It will undoubtedly take as many years for us to gain impact on the treatment of vitiligo. Acitretin and its pre- experience with biologics, but the cost of these drugs has cursor etretinate were both approved for psoriasis but have prohibited not only their widespread use in the market- found an important role in skin cancer prevention. place but also our ability to study them. It http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Dermatology American Medical Association

Advances in Psoriasis

JAMA Dermatology , Volume 141 (12) – Dec 1, 2005

Loading next page...
 
/lp/american-medical-association/advances-in-psoriasis-b0phvlytYd
Publisher
American Medical Association
Copyright
Copyright 2005 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-6068
eISSN
2168-6084
DOI
10.1001/archderm.141.12.1589
pmid
16365263
Publisher site
See Article on Publisher Site

Abstract

EDITORIAL ORE TREATMENTS FOR PSORIASIS HAVE Experience with biologic therapy is analogous to the been introduced during the past 25 introduction of methotrexate for psoriasis. The first ar- years than for all other diseases in der- ticle on methotrexate for this disease was published in matology combined. The impact of 1961. In those days, methotrexate was administered in- M those treatments on all dermatologic travenously, on a daily basis and in dosages as high as disease has been profound. For example, psoralen– 70 mg/wk, and patients died. It was not until 1971 when UV-A was introduced for psoriasis but has changed the Weinstein and Frost published their article about the treatment of cutaneous T-cell lymphoma. Narrowband weekly regimen that is still in use. UV-B was developed for psoriasis but has had a major It will undoubtedly take as many years for us to gain impact on the treatment of vitiligo. Acitretin and its pre- experience with biologics, but the cost of these drugs has cursor etretinate were both approved for psoriasis but have prohibited not only their widespread use in the market- found an important role in skin cancer prevention. place but also our ability to study them. It

Journal

JAMA DermatologyAmerican Medical Association

Published: Dec 1, 2005

References